Biognosys, a Swiss ETH spin-off and pioneer in proteomics, has attracted venture capital from experienced investors including Syngenta Ventures. Biognosys is the first company that can quantify every protein in biological samples fast and precisely. This is opening up entirely new options for precise diagnostics, personalised medicine and intelligent crop design.
Biognosys, the leader in targeted proteomics mass spectrometry founded in 2008 as an ETH Zurich spin off, has announced that it has closed a CHF2.7m Series A financing round with experienced venture capitalists. The round includes Hellmut Kirchner, co-founder of Germany’s first venture fund TVM, Redalpine Capital I that had lead the seed round in 2009, ZKB start-up finance, venture arm of Cantonal Bank of Zurich, several private investors and Syngenta Ventures, corporate venture arm of agro-chemicals leader Syngenta. Subsequently, Ignacio Martinez will represent Syngenta Ventures at Biognosys’ board of directors. The board is further strengthened by Hellmut Kirchner and by Harry Welten who has served as CFO for several listed biotech and pharmaceutical companies.
"The closing of this financing round reflects the investor’s confidence in Biognosys’ team and our proprietary targeted proteomics technology," said Oliver Rinner, CEO of Biognosys. "Syngenta Ventures and the new investors are a great addition to our company. With the completion of this Series A round, we are well capitalised to bring Biognosys to the next phase of growth."
Biognosys delivers a technology platform for diagnostics, pharmaceutical, biotech and healthcare companies. Since operations started in 2010, the ETH spin-off has provided its targeted proteomics technology to identify and quantify proteins for companies such as Novartis, Pfizer, Integrated Diagnostics, and Philips. Recently Biognosys started exploring additional options in the field of intelligent crop design.